Nisa Investment Advisors LLC Sells 10,097 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 85.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,770 shares of the company's stock after selling 10,097 shares during the quarter. Nisa Investment Advisors LLC's holdings in Janux Therapeutics were worth $48,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. grew its stake in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after buying an additional 1,200,000 shares during the last quarter. FMR LLC grew its stake in Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after buying an additional 845,266 shares during the last quarter. Janus Henderson Group PLC grew its stake in Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after buying an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP grew its stake in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after buying an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after buying an additional 986,750 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Down 4.9%

Shares of JANX traded down $1.35 during trading hours on Friday, hitting $26.40. The company had a trading volume of 908,736 shares, compared to its average volume of 878,789. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -19.41 and a beta of 2.86. The business has a fifty day moving average of $24.62 and a 200-day moving average of $31.29. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James Financial initiated coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target for the company. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average price target of $91.89.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider directly owned 82,139 shares of the company's stock, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.10% of the company's stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.